A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Summary

The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.

Timeline

Start

2016-09-14

Primary completion

2017-06-19

Completion

2019-05-08

Outcome

Met primary endpoint

registry analysis (superiority test); Induction: Placebo vs Induction: 30 mg Mirikizumab; p = 0.009; Risk Difference (RD) 29.4 (95% CI 16.9 to 41.9); Regression, Logistic NCT02899988 ↗

Drugs

Indications